|Bid||0.00 x 1200|
|Ask||0.00 x 1200|
|Day's Range||78.44 - 79.59|
|52 Week Range||75.77 - 107.25|
|Beta (3Y Monthly)||0.99|
|PE Ratio (TTM)||21.49|
|Earnings Date||Apr 25, 2019|
|Forward Dividend & Yield||4.28 (5.31%)|
|1y Target Est||92.18|
While Pfizer's (PFE) key drugs like Ibrance and Xeljanz are likely to drive Q1 sales, genericization of key drugs and weak sales in the EH segment will hurt.
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead to an earnings beat for the company in Q1.
is expected to report quarterly earnings of $2.06 a share on sales of $7.8 billion before the market opens Thursday, Apr. 25, based on a FactSet survey of 14 analysts. Quarterly estimates have risen less than 1 cent a share in the past month. AbbVie is currently trading at a price-to-forward-earnings ratio of 8.9 based on the 12-month estimates of 16 analysts surveyed by FactSet.
Here’s what investors should look for on Thursday as these two pharmaceutical giants report first-quarter earnings.
Biogen (BIIB) beats estimates for both earnings and sales in the first quarter fueled mainly by strong performance of its muscle disease drug, Spinraza in international markets.
AbbVie (ABBV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on April 22) BIONDVAX PHARMA/S ADR (NASDAQ: BVXV ) Eidos Therapeutics ...
AbbVie Inc said on Tuesday that the U.S. Food and Drug Administration approved its Skyrizi drug as a treatment for plaque psoriasis at a time when its blockbuster psoriasis drug, Humira, faces patent pressures. Plaque psoriasis is the most common form of psoriasis, a a chronic skin condition. The approval of Skyrizi, an injectable drug, is based on results from AbbVie's global Phase 3 psoriasis program, which assessed the safety and efficacy of the drug in adults with moderate to severe plaque psoriasis.
AbbVie Inc. shares ticked higher after the drug maker said Tuesday the Food and Drug Administration approved its psoriasis treatment Skyrizi. AbbVie shares rose 0.8% after hours, following a 0.7% rise to close the regular session at $78.66. In clinical trials, the drug cleared up skin by 90% in around 80% of patients and by 100% in just over half of patients, AbbVie said.
- Approval based on clinical trials showing people treated with SKYRIZI™ (risankizumab-rzaa) every 12 weeks - four doses a year after two initial doses - achieved high levels of durable skin clearance ...
Strong growth of Imbruvica and Mavyret are expected to drive AbbVie (ABBV) first-quarter sales. Declining ex-U.S. Humira sales are likely to be an overhang on the top line.
While sales of Biogen's (BIIB) MS franchise are expected to decline in the first quarter of 2019 that of Spinraza are likely to increase.
With negative earnings revisions, the healthcare sector is expected to witness earnings growth of 1.8% in the first quarter, suggesting smooth trading for healthcare ETFs.
AbbVie (ABBV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Health Canada Approves SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis
When most people think of marijuana stocks, the last thing they think of is dividends. Furthermore, U.S. investors in the marijuana space tend to currently focus on a handful of Canadian companies which have enjoyed the opportunity to list on U.S. exchanges. The company remains one of the most popular marijuana pharmaceuticals developers.
J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2019 and raises 2019 guidance for operational sales and adjusted operational EPS growth. Shares up in pre-market trading.